USMLE Step 3 Quiz: Pulmonary Embolism And Anticoagulation Follow Up

What this quiz covers

This quiz focuses on Pulmonary Embolism And Anticoagulation Follow Up, giving you a quick way to practice the rules, question types, and explanations that matter most for USMLE Step 3.

How to use this quiz

Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.

Question 1

1. Reassure and schedule routine follow-up because he is already anticoagulated
2. Obtain CT pulmonary angiography to evaluate for recurrent pulmonary embolism (correct answer)
3. Stop apixaban and start warfarin without parenteral bridging therapy
4. Start NSAIDs for pleurisy and defer imaging until symptoms persist one week

Explanation: This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's missed apixaban doses, new pleuritic chest pain, dyspnea, tachycardia, and hypoxia are critical for decision-making. The correct answer addresses these factors by suggesting CT pulmonary angiography to evaluate for recurrent pulmonary embolism, demonstrating the application of clinical guidelines for suspected recurrence in nonadherent patients. A common distractor might suggest reassurance without imaging, which fails to consider the risk of recurrence due to missed doses. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.

Question 2

1. Hold warfarin, administer reversal, and evaluate for gastrointestinal bleeding source urgently (correct answer)
2. Continue warfarin and add a proton pump inhibitor without further evaluation
3. Switch to aspirin monotherapy and schedule outpatient colonoscopy in three months
4. Increase warfarin dose to maintain INR 3.5–4.5 for recurrent PE prevention

Explanation: This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's INR of 3.8, dark stools, lightheadedness, hemoglobin drop, and recent ibuprofen use are critical for decision-making. The correct answer addresses these factors by suggesting holding warfarin, administering reversal, and urgently evaluating for gastrointestinal bleeding, demonstrating the application of clinical guidelines for major bleeding events. A common distractor might suggest continuing warfarin and adding a proton pump inhibitor, which fails to consider the urgency of reversal and evaluation in active bleeding. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.

Question 3

1. Fixed-dose apixaban is preferred due to its favorable safety profile in all populations.
2. Low-molecular-weight heparin is the only appropriate long-term option.
3. Dabigatran should be used as it is not affected by body weight.
4. Warfarin is a preferred agent due to the ability to monitor its effect with the INR. (correct answer)

Explanation: When treating venous thromboembolism in patients with extreme obesity (BMI >40 kg/m² or weight >120 kg), you need to consider how body weight affects anticoagulant dosing and monitoring capabilities. Warfarin remains the preferred choice for morbidly obese patients because it can be precisely monitored and dose-adjusted using INR values, regardless of body weight. The INR directly measures the anticoagulant effect, allowing clinicians to ensure therapeutic levels are maintained even in patients with altered drug distribution due to extreme obesity. Choice A is incorrect because fixed-dose direct oral anticoagulants (DOACs) like apixaban haven't been adequately studied in patients weighing >120 kg. The standard fixed doses may provide subtherapeutic levels in morbidly obese patients, potentially leading to treatment failure. Choice B is wrong because low-molecular-weight heparin is typically used for short-term or bridging therapy, not long-term management. It's also impractical for extended outpatient use due to the need for daily injections. Choice C is incorrect because dabigatran, like other DOACs, lacks sufficient data in extreme obesity. While it's true that dabigatran has less weight-based dosing variation than some other drugs, there's still concern about adequate drug exposure in patients >120 kg, and unlike warfarin, you cannot monitor its anticoagulant effect with routine lab tests. Remember: In extreme obesity (BMI >40 or weight >120 kg), choose anticoagulants that allow therapeutic monitoring. Warfarin's ability to be monitored with INR makes it the safest choice when DOAC efficacy data is limited.

Question 4

1. Stop apixaban as the initial treatment course is complete.
2. Stop apixaban and begin daily low-dose aspirin.
3. Continue apixaban indefinitely with periodic reassessment. (correct answer)
4. Obtain a ventilation-perfusion scan to assess for residual clot.

Explanation: For a first-time unprovoked pulmonary embolism, the risk of recurrence after stopping anticoagulation is high (approximately 10% in the first year). In a patient with a low bleeding risk, guidelines recommend extended anticoagulation therapy to prevent recurrence. This involves continuing apixaban indefinitely, with at least annual reassessment of the risks and benefits. Stopping therapy would leave her at high risk for a recurrent, potentially fatal PE. Aspirin is significantly less effective than anticoagulation for VTE prevention. Follow-up imaging is not recommended as it does not change management.

Question 5

1. Continue rivaroxaban, as it is effective and convenient.
2. Stop rivaroxaban and switch to therapeutic-dose enoxaparin. (correct answer)
3. Stop rivaroxaban and switch to warfarin with a target INR of 2.0-3.0.
4. Discontinue all anticoagulation until after delivery.

Explanation: Direct oral anticoagulants (DOACs) like rivaroxaban are contraindicated in pregnancy due to lack of safety data and potential for fetotoxicity. Warfarin is teratogenic, especially during the first trimester. The anticoagulant of choice during pregnancy is low-molecular-weight heparin (LMWH), such as enoxaparin, as it does not cross the placenta. Discontinuing anticoagulation is unsafe due to the high risk of recurrent VTE, which is further increased by pregnancy.

Question 6

1. Testing should be performed now to determine if lifelong anticoagulation is required.
2. Testing is not indicated because the PE was provoked and the results will not alter management. (correct answer)
3. Testing for Factor V Leiden is mandatory to guide her future contraceptive choices.
4. Testing should have been done before starting apixaban to rule out contraindications.

Explanation: This patient had a pulmonary embolism provoked by a major, modifiable risk factor (oral contraceptives). The standard treatment is a finite course (3 months) of anticoagulation. Testing for inherited thrombophilias is generally not recommended in this setting because the results would not change the management plan. The presence of a thrombophilia would not extend the duration of therapy for a clearly provoked event. Regardless of thrombophilia status, she will be advised to avoid estrogen-containing contraceptives in the future.

Question 7

1. Repeat CT pulmonary angiography.
2. Ventilation-perfusion (V/Q) scan. (correct answer)
3. Right heart catheterization.
4. Six-minute walk test.

Explanation: This patient's presentation is highly suspicious for chronic thromboembolic pulmonary hypertension (CTEPH), a serious complication of acute PE. The initial screening test of choice for CTEPH is a ventilation-perfusion (V/Q) scan due to its high sensitivity; a normal V/Q scan essentially rules out CTEPH. While CTPA may show signs of chronic PE, it is less sensitive than a V/Q scan. Right heart catheterization is the gold standard for confirming the diagnosis of pulmonary hypertension and assessing its severity, but it is an invasive procedure performed after non-invasive screening suggests the diagnosis. A six-minute walk test assesses functional capacity but is not diagnostic.

Question 8

1. Apixaban.
2. Warfarin with a target INR of 2.0-3.0. (correct answer)
3. Rivaroxaban.
4. Low-dose aspirin monotherapy.

Explanation: For patients with antiphospholipid syndrome (APS), particularly high-risk patients (triple-positive or with a history of arterial thrombosis), warfarin remains the standard of care for treating VTE. Clinical trials have suggested that direct oral anticoagulants (DOACs) may be associated with a higher rate of recurrent thrombosis, especially arterial events, compared to warfarin in this specific population. Therefore, DOACs like apixaban and rivaroxaban should be avoided. Aspirin monotherapy is inadequate for VTE treatment.

Question 9

1. He must avoid all strenuous activity until his 3-month course of anticoagulation is complete.
2. He can begin a gradual return to his training regimen as tolerated, avoiding contact sports. (correct answer)
3. He should remain on bed rest for two more weeks to prevent thrombus dislodgement.
4. He can resume training immediately with no restrictions, as anticoagulation is protective.

Explanation: Early ambulation and a gradual return to physical activity are encouraged after an acute PE as soon as the patient is hemodynamically stable and symptoms allow. Prolonged immobility is a risk factor for VTE. The main restriction while on anticoagulation is to avoid activities with a high risk of traumatic injury and bleeding (e.g., contact sports). Therefore, a gradual, sensible return to running is appropriate. Bed rest is contraindicated. An immediate return to full-intensity training without a gradual ramp-up is not advisable.

Question 10

1. Administer 2.5 mg of oral vitamin K.
2. Continue the current warfarin dose and advise him to avoid antibiotics.
3. Admit the patient for fresh frozen plasma transfusion.
4. Hold the warfarin dose for today and recheck the INR in 1-2 days. (correct answer)

Explanation: When managing warfarin overdose, your approach depends on the degree of INR elevation and presence of bleeding. This patient has a supratherapeutic INR (4.5) without active bleeding, likely due to ciprofloxacin inhibiting warfarin metabolism through CYP450 interactions. For INR levels between 4.5-10 without bleeding, the standard approach is to hold warfarin temporarily and monitor closely. The INR will naturally decrease as warfarin's effect wanes (warfarin has a half-life of 36-42 hours). This allows for safe correction without risking overcorrection that could lead to thrombotic complications. Choice D is correct because holding warfarin and rechecking INR in 1-2 days allows controlled monitoring of the INR decline while maintaining anticoagulation benefits as the ciprofloxacin effect diminishes. Choice A (oral vitamin K 2.5 mg) would be appropriate for INR >10 without bleeding, but risks overcorrection and warfarin resistance for several days. Choice B ignores the dangerous INR elevation - continuing warfarin could worsen the coagulopathy, and avoiding all antibiotics isn't realistic long-term management. Choice C (FFP transfusion) is reserved for life-threatening bleeding or emergency surgery needs, as it's expensive, carries transfusion risks, and provides only temporary reversal. Key strategy: Remember the INR thresholds for warfarin management: 3-5 without bleeding = hold doses and monitor; 5-9 without bleeding = hold and consider low-dose vitamin K; >9 or any bleeding = vitamin K; life-threatening bleeding = vitamin K plus FFP/PCC.

Question 11

1. No prophylaxis is needed as her PE was fully treated.
2. She requires bridging therapy with enoxaparin and post-operative warfarin.
3. She should receive standard peri-operative pharmacologic prophylaxis per surgical guidelines. (correct answer)
4. She should be restarted on her full treatment dose of apixaban post-operatively.

Explanation: A history of VTE places a patient at a higher baseline risk for future events, especially in high-risk situations like major surgery. However, she is not on active treatment. The correct approach is to risk-stratify her for the specific procedure (hysterectomy is moderate-to-high risk) and provide standard peri-operative VTE prophylaxis (e.g., LMWH or unfractionated heparin) according to established guidelines. Restarting full-dose anticoagulation or using bridging therapy is not indicated, as she does not have an active clot. Forgoing prophylaxis entirely would be unsafe given her history.

Question 12

1. Leave the IVC filter in place indefinitely for long-term protection.
2. No further intervention is needed as the filter has resolved the acute risk.
3. Initiate therapeutic anticoagulation but leave the filter in place permanently.
4. Initiate therapeutic anticoagulation for 3-6 months and schedule filter retrieval. (correct answer)

Explanation: When you encounter questions about IVC filters on Step 3, think systematically about the indication for placement, the type of filter used, and the current clinical status. IVC filters are temporary solutions, not permanent fixes for venous thromboembolism. This patient had a clear contraindication to anticoagulation (intracranial hemorrhage) at the time of his PE, making a retrievable IVC filter the appropriate choice for temporary protection. Now that his neurological status has stabilized and the bleeding risk has resolved, the management strategy should shift to evidence-based VTE treatment. The correct approach is D) Initiate therapeutic anticoagulation for 3-6 months and schedule filter retrieval. With the contraindication resolved, anticoagulation becomes the gold standard for PE treatment. Retrievable filters should be removed once they're no longer needed to avoid long-term complications like filter fracture, migration, or caval thrombosis. A is incorrect because indefinite filter placement exposes patients to unnecessary long-term risks when anticoagulation is now safe. B misses that the underlying thrombotic risk from his PE still requires treatment—the filter only prevented further embolization, it didn't treat the existing clot. C represents a common misconception; there's no benefit to keeping the filter once anticoagulation is started, and it only adds risk. Key strategy: For IVC filter questions, always ask yourself: "Is the contraindication to anticoagulation still present?" If not, plan for filter removal and standard VTE therapy. Retrievable filters should actually be retrieved when safe to do so.

Question 13

1. Discontinue enoxaparin and increase the warfarin dose.
2. Continue both enoxaparin and warfarin at their current doses. (correct answer)
3. Administer fresh frozen plasma to rapidly increase the INR.
4. Discontinue both medications and switch to apixaban.

Explanation: When treating acute VTE with warfarin, bridging with a parenteral anticoagulant (like enoxaparin) is required. The parenteral agent should be continued for a minimum of 5 days AND until the INR has been in the therapeutic range (≥2.0) for at least 24 hours. Although this patient has been treated for 5 days, his INR is still subtherapeutic at 1.7. Therefore, both enoxaparin and warfarin must be continued. Discontinuing the enoxaparin prematurely would place him at risk for thrombus extension or recurrence.

Question 14

1. His history makes the Pulmonary Embolism Rule-out Criteria (PERC) inapplicable. (correct answer)
2. He meets PERC criteria, so a PE can be safely ruled out without further testing.
3. A V/Q scan is now the mandatory next step, superseding CT angiography.
4. His history is not relevant as the previous event was more than a year ago.

Explanation: A prior history of DVT or PE is one of the eight criteria in the PERC rule. If any criterion is present, the rule is not met, and PE cannot be ruled out on clinical grounds alone. This patient's history automatically places him in a higher pre-test probability category where further diagnostic testing, such as a D-dimer assay or imaging, is warranted. Stating that he meets PERC criteria is incorrect. His history is a major risk factor for recurrence and is highly relevant. The choice between V/Q and CTA depends on other factors and is not mandated by the history alone.

Question 15

1. Rivaroxaban 15 mg daily.
2. Apixaban 5 mg twice daily.
3. Dabigatran 75 mg twice daily.
4. Warfarin with enoxaparin bridge. (correct answer)

Explanation: This patient has severe chronic kidney disease (CKD) with a GFR <30 mL/min. Most direct oral anticoagulants (DOACs) are renally cleared and are either contraindicated or require caution and have limited data in severe CKD. Rivaroxaban and dabigatran are contraindicated in the US for VTE treatment with a CrCl <30 mL/min. While apixaban can be used, its use is based on pharmacokinetic data rather than large trials in this population. Warfarin is not renally cleared and is the most studied and recommended oral anticoagulant for patients with severe CKD or end-stage renal disease. It should be initiated with a parenteral bridge (e.g., heparin or enoxaparin) until the INR is therapeutic.

Question 16

1. A repeat CT scan is needed to determine when you can stop anticoagulation.
2. Routine follow-up imaging is not recommended as it rarely alters the management plan. (correct answer)
3. A V/Q scan should be performed instead, as it involves less radiation.
4. A CT scan is necessary; residual clot would mandate lifelong therapy.

Explanation: Routine imaging (either CT or V/Q scan) to assess for clot resolution after a course of treatment for acute PE is not recommended in asymptomatic patients. The findings do not reliably predict recurrence risk and do not alter the planned duration of therapy, which is based on whether the PE was provoked or unprovoked and the patient's bleeding risk. Such imaging would lead to unnecessary radiation exposure, cost, and risk of contrast-induced nephropathy. Residual thrombus is a common finding and does not automatically necessitate lifelong therapy, especially for a provoked PE.

Question 17

1. Continue rivaroxaban and start oral iron without investigating potential bleeding source
2. Evaluate for occult gastrointestinal bleeding while reassessing anticoagulation risks and benefits (correct answer)
3. Increase rivaroxaban dose because microcytosis indicates recurrent pulmonary embolism
4. Stop anticoagulation immediately without evaluation because guaiac positivity is definitive

Explanation: This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's progressive fatigue, exertional dyspnea, anemia, microcytosis, and positive stool guaiac are critical for decision-making. The correct answer addresses these factors by suggesting evaluation for occult gastrointestinal bleeding while reassessing anticoagulation risks and benefits, demonstrating the application of clinical guidelines for managing chronic bleeding on DOACs. A common distractor might suggest continuing rivaroxaban without investigation, which fails to consider the need to identify and address the bleeding source. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.

Question 18

1. Evaluate for recurrent VTE and initiate therapeutic anticoagulation while awaiting imaging (correct answer)
2. Reassure because low INR is expected with diet changes and no action is needed
3. Stop warfarin and start aspirin because INR monitoring is unreliable
4. Administer vitamin K to reverse warfarin and prevent bleeding complications

Explanation: This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's subtherapeutic INR of 1.5, new unilateral leg swelling, mild dyspnea, tachycardia, hypoxia, and recent diet changes are critical for decision-making. The correct answer addresses these factors by suggesting evaluation for recurrent VTE and initiating therapeutic anticoagulation while awaiting imaging, demonstrating the application of clinical guidelines for subtherapeutic anticoagulation. A common distractor might suggest reassurance due to diet changes, which fails to consider the clinical signs of possible recurrence. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.

Question 19

1. Hold warfarin, resuscitate, and treat suspected major gastrointestinal bleeding urgently (correct answer)
2. Continue warfarin because INR is in range and bleeding will self-resolve
3. Increase warfarin dose to prevent thrombosis during acute illness and hypotension
4. Switch to prophylactic-dose anticoagulation only and avoid endoscopic evaluation

Explanation: This question tests the understanding of pulmonary embolism management and anticoagulation follow-up in a clinical context relevant to USMLE Step 3. The principle focus is on applying clinical guidelines for anticoagulation management and recognizing complications arising from therapy. In this scenario, factors such as the patient's black tarry stools, dizziness, hypotension, tachycardia, and significant hemoglobin drop despite therapeutic INR are critical for decision-making. The correct answer addresses these factors by suggesting holding warfarin, resuscitating, and urgently treating major gastrointestinal bleeding, demonstrating the application of clinical guidelines for major bleeding events. A common distractor might suggest continuing warfarin, which fails to consider the life-threatening nature of the bleed. To prepare for similar questions, students should focus on understanding anticoagulation management guidelines, recognize symptoms indicative of complications, and practice applying this knowledge to case scenarios.

Question 20

1. Administer andexanet alfa to reverse the apixaban.
2. Reduce the apixaban dose to 2.5 mg twice daily.
3. Reassure the patient and continue the current therapy. (correct answer)
4. Discontinue apixaban and switch to warfarin.

Explanation: Minor, or 'nuisance,' bleeding such as increased bruising and minor epistaxis is a common side effect of anticoagulation. In the absence of major or clinically significant bleeding, the best course of action is to reassure the patient that these effects are expected and that the benefit of preventing a recurrent PE outweighs the inconvenience of this minor bleeding. Andexanet alfa is for life-threatening bleeding. Reducing the dose would be inappropriate for VTE treatment and would undertreat the patient. Switching to warfarin is unlikely to reduce minor bleeding and is less convenient.